Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 10/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31036743 | 0.98 | CES2 (0.41) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL27212835 | 0.98 | CES2 (0.41) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL28134679 | 0.94 | DGAT1 (0.40) | DGAT1MEN1MAPTKMT2AATM | |
| SCHEMBL12223368 | 0.90 | DGAT1 (0.38) | DGAT1MEN1MAPTKMT2AATM | |
| SCHEMBL17381369 | 0.88 | GPR84 (0.55) | MEN1MAPTKMT2A | |
| SCHEMBL12660586 | 0.86 | CYP4F2 (0.43) | DGAT1MEN1KMT2A | |
| SCHEMBL18612496 | 0.86 | CES2 (0.46) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL19509962 | 0.86 | CES2 (0.46) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL19509955 | 0.86 | CES2 (0.41) | DGAT1MEN1MAPTKMT2AATM | |
| SCHEMBL28004342 | 0.86 | DGAT1 (0.38) | DGAT1MEN1MAPTKMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4556459-A1 | COMPOUND SERVING AS PRODUCTION INTERMEDIATE OF AMINO LIPID OR SALT THEREOF, AND METHOD FOR PRODUCING AMINO LIPID COMPOUND USING SAME | FUJIFILM Corporation (JP) | 2025-05-21 | — | — | EP | disclosed |
| US-20250145560-A1 | COMPOUND AS MANUFACTURING INTERMEDIATE OF AMINOLIPID OR SALT THEREOF AND METHOD FOR MANUFACTURING AMINOLIPID COMPOUND USING THE COMPOUND | FUJIFILM CORPORATION (JP) | 2025-05-08 | — | — | US | disclosed |
| CN-119487010-A | Compound as intermediate for producing amino lipid or salt thereof, and method for producing amino lipid compound using same | 富士胶片株式会社 | 2025-02-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145560-A1 | COMPOUND AS MANUFACTURING INTERMEDIATE OF AMINOLIPID OR SALT THEREOF AND METHOD FOR MANUFACTURING AMINOLIPID COMPOUND USING THE COMPOUND | CETP, LCAT, LIPA | DGAT1 196/4885MEN1 641/4885MAPT 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.